The tumor heterogeneity was attributed to both genetic and non‐genetic mechanisms acting at various intervals for targeted drugs, including EGFR‐TKIs in NSCLC patients with EGFR mutations.26, 27. The gene discussed is EGFR; the disease is neoplasm.